ERBB2 and cancer: These include mutations in key genes such as RAS and BRAF that activate bypass signaling pathways, alterations in the EGFR receptor and its specific ligands that diminish drug binding, and the activation of alternative growth pathways such as MET and HER2, which provide cancer cells with escape routes from therapy.